Eli Lilly's Mounjaro (Tirzepatide) has emerged as a game-changer in tackling two major health challenges—type 2 diabetes and obesity. By mimicking the effects of two crucial hormones, GLP-1 and GIP, Mounjaro not only regulates blood sugar levels but also suppresses appetite, leading to significant weight loss. Backed by clinical trials, it is positioned as a promising option in India’s weight-loss medication landscape. However, its pricing—₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial—raises concerns about accessibility in India’s cost-sensitive market.

Recognizing the importance of this development, SPER Market Research conducted an in-depth study involving 95 diabetologists and endocrinologists to gauge their perceptions and sentiments toward Mounjaro. The findings from this research offer valuable insights for shaping discussions and strategies around its adoption.

Despite pricing challenges, Mounjaro has received positive feedback from healthcare specialists, with 79% of them "very likely" to prescribe it. Their confidence stems from the drug’s dual-action mechanism, its ability to achieve significant A1c reductions, and its potential cardioprotective benefits. However, some concerns remain, particularly regarding side effects like nausea and vomiting, as well as the lack of long-term safety data specific to the Indian population. These factors contribute to a balanced yet cautiously optimistic outlook on its use for chronic weight management and diabetes control.

When compared to competitors like Wegovy and Ozempic, Mounjaro stands out due to its superior clinical efficacy and broader health benefits. While Wegovy exclusively targets GLP-1 and Ozempic is Primarily For Diabetes Management, Mounjaro’s dual mechanism provides a more comprehensive approach. That said, its high cost and limited real-world data may slow its market penetration. As India confronts a growing obesity epidemic, innovative treatments like Mounjaro could play a crucial role—provided affordability and long-term safety concerns are effectively addressed.